8-OH-DPAT

**8-OH-DPAT** is a synthetic aminotetralin derivative and research compound, developed in the 1980s, used primarily as a pharmacological tool in neuroscience. It is a potent and selective **5-HT1A receptor full agonist**, with high affinity and selectivity originally believed to be exclusive, but it also has agonist activity at the **5-HT7 receptor** and acts as a serotonin reuptake inhibitor and releasing agent. Its enantiomers show stereoselectivity, with the R-enantiomer displaying greater agonist efficacy at 5-HT1A. In animal models, 8-OH-DPAT is used to probe serotonin function and has shown antidepressant, anxiolytic, serenic, anorectic, antiemetic, hypothermic, hypotensive, bradycardic, hyperventilative, and analgesic effects. It is experimental and not approved for therapeutic use in humans, but is widely employed in the study of mood, cognition, sexual behavior, and neurodegenerative diseases such as Parkinson’s disease, where it demonstrates neuroprotective and anti-inflammatory effects via cytokine modulation[1][2][3][7][13].

Other names

8-Hydroxy-2-(di-n-propylamino)tetralin8-Hydroxy-DPAT7-(Dipropylamino)-5,6,7,8-tetrahydronaphthalen-1-ol1-Naphthalenol,7-(dipropylamino)-5,6,7,8-tetrahydro-dl-8-Hydroxy-2-(dipropylamino)tetralinCHEBI:73364CHEMBL56CHEMBL-56CHEMBL 56(+/-)-8-hydroxy-2-(dipropylamino)tetralin hydrobromide8-Hydroxy-2-dipropylaminotetralin hydrobromide8-OH-DPAT HBr8-OH-DPAT hydrobromide78950-78-476135-31-4